Physician

Sudhir Bhargav Vyakaranam, MD

According to 2025 Medicare claims, Sudhir Vyakaranam, MD (NPI: 1407019037) practices nephrology in the Elkhart-Goshen, IN market, with the plurality of this provider's patient population coming from Elkhart, IN. This provider's primary affiliated billing organization is NEPHROLOGY PHYSICIANS LLC (NPI: 1518996719; TIN: 352082018) and primary practice location at 46628-6117. Vyakaranam is affiliated with the CHA ACO, LLC (ACO ID: A2207), participating under the MSSP model.

Vyakaranam's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 559 traditional Medicare patients, billed 1,835 HCPCS/CPT codes, and received $185,379 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 5,126 prescription claims across 611 beneficiaries totaling $596,019 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 238 claims. Open Payments data shows 41 records totaling $18,673. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $356,374 to $185,379. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $615 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	966	17,435	$356,374
2016	970	18,211	$349,980
2017	1,030	17,528	$355,376
2018	922	13,424	$312,280
2019	895	8,684	$326,576
2020	743	7,092	$274,987
2021	685	5,071	$257,902
2022	648	2,409	$241,757
2023	590	2,092	$229,866
2024	559	1,835	$185,379

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	551	5,459	$906,856
2016	567	5,661	$495,151
2017	599	5,963	$549,553
2018	581	5,668	$371,095
2019	538	4,679	$410,224
2020	545	4,932	$290,940
2021	543	4,660	$269,618
2022	563	4,359	$348,506
2023	554	4,608	$492,110
2024	611	5,126	$596,019

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	13	331	$22,360
2016	11	247	$11,067
2017	23	321	$13,556
2018	22	288	$11,710
2019	N/R	243	$6,454
2020	N/R	226	$6,753
2021	N/R	141	$4,405
2022	N/R	181	$4,331
2023	N/R	187	$4,747
2024	N/R	238	$5,957

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	104	117	$122
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	40	50	$93
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	101	272	$85
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	299	565	$59
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	132	340	$58

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	204	7,630	$141,011
Velphoro	Sucroferric Oxyhydroxide	31	990	$106,964
Xphozah	Tenapanor Hcl	11	510	$49,673
Jardiance	Empagliflozin	53	2,252	$45,566
Kerendia	Finerenone	50	1,920	$41,617

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	61	$1,129
J7515	Cyclosporine, oral, 25 mg	N	N/R	16	$1,114
J7500	Azathioprine, oral, 50 mg	N	N/R	13	$876
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	20	$872
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	54	$815

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	37	$781	Otsuka America Pharmaceutical, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	4	$17,892	VERTEX PHARMACEUTICALS INCORPORATED
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sudhir Bhargav Vyakaranam, MD?

Tedicare shows public-source Medicare data for Sudhir Bhargav Vyakaranam, MD (NPI 1407019037), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sudhir Bhargav Vyakaranam, MD have ACO affiliation data?

Sudhir Bhargav Vyakaranam, MD is shown with ACO affiliation data for CHA ACO, LLC (MSSP, ACO ID A2207).

What billing organization is linked to Sudhir Bhargav Vyakaranam, MD?

Sudhir Bhargav Vyakaranam, MD is linked to NEPHROLOGY PHYSICIANS LLC (billing NPI 1518996719) in the available physician profile data.

Does Sudhir Bhargav Vyakaranam, MD have Open Payments data?

Sudhir Bhargav Vyakaranam, MD has 41 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.